Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Chipscreen Approved to Start China Trials for Novel Oral Psoriasis Therapy

publication date: Nov 3, 2023

Shenzhen Chipscreen Biosciences was approved to start China clinical trials of its novel oral therapy for psoriasis. CS32582 is a small molecule, selective allosteric inhibitor of Tyrosine Kinase 2 (TYK2) that was developed by Chipscreen. It specifically binds to its regulatory pseudokinase JH2 domain. Because it does not inhibit the JAK1, JAK2 and JAK3 members of the same family, CS32582 is expected to combine therapeutic efficacy with a favorable safety profile. Chipscreen said the candidate showed significant efficacy in mouse models of psoriasis. More details....

Stock Symbol: (SHA: 688321)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here